Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 13 | 2024 | 935 | 1.710 |
Why?
|
| Liver Neoplasms | 13 | 2024 | 1308 | 1.540 |
Why?
|
| Liver Cirrhosis | 13 | 2024 | 823 | 1.270 |
Why?
|
| Liver Transplantation | 6 | 2020 | 1014 | 0.770 |
Why?
|
| Alcohol Drinking | 2 | 2024 | 337 | 0.720 |
Why?
|
| Hepatitis C | 4 | 2023 | 365 | 0.710 |
Why?
|
| Early Detection of Cancer | 4 | 2024 | 349 | 0.640 |
Why?
|
| Alcoholic Beverages | 1 | 2019 | 18 | 0.640 |
Why?
|
| End Stage Liver Disease | 3 | 2018 | 178 | 0.640 |
Why?
|
| Religion | 1 | 2019 | 49 | 0.620 |
Why?
|
| Liver Diseases | 2 | 2018 | 362 | 0.560 |
Why?
|
| Hepacivirus | 3 | 2016 | 241 | 0.560 |
Why?
|
| Alcoholism | 1 | 2019 | 230 | 0.540 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 136 | 0.500 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 87 | 0.500 |
Why?
|
| Digestive System Neoplasms | 1 | 2015 | 14 | 0.490 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2015 | 54 | 0.470 |
Why?
|
| alpha-Fetoproteins | 2 | 2024 | 131 | 0.440 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 78 | 0.430 |
Why?
|
| Antiviral Agents | 2 | 2016 | 747 | 0.410 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2023 | 57 | 0.410 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 430 | 0.330 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 387 | 0.300 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2008 | 64 | 0.290 |
Why?
|
| Veterans | 1 | 2018 | 1726 | 0.280 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 223 | 0.260 |
Why?
|
| Quality Improvement | 2 | 2022 | 625 | 0.250 |
Why?
|
| Prospective Studies | 10 | 2024 | 6033 | 0.250 |
Why?
|
| Risk Factors | 11 | 2024 | 10010 | 0.230 |
Why?
|
| Phospholipases A2, Calcium-Independent | 1 | 2024 | 13 | 0.230 |
Why?
|
| Humans | 27 | 2024 | 123171 | 0.220 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 233 | 0.200 |
Why?
|
| Graft Survival | 2 | 2014 | 525 | 0.200 |
Why?
|
| Middle Aged | 14 | 2024 | 25994 | 0.190 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2020 | 44 | 0.170 |
Why?
|
| Program Development | 1 | 2020 | 191 | 0.170 |
Why?
|
| United States | 4 | 2024 | 10631 | 0.160 |
Why?
|
| History, 15th Century | 1 | 2019 | 13 | 0.160 |
Why?
|
| History, Medieval | 1 | 2019 | 26 | 0.160 |
Why?
|
| History, 16th Century | 1 | 2019 | 27 | 0.160 |
Why?
|
| History, Ancient | 1 | 2019 | 54 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 2106 | 0.160 |
Why?
|
| Pentanoic Acids | 1 | 2018 | 3 | 0.160 |
Why?
|
| Caspase Inhibitors | 1 | 2018 | 29 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2020 | 176 | 0.150 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 119 | 0.150 |
Why?
|
| Cystatin C | 1 | 2018 | 49 | 0.150 |
Why?
|
| Obesity | 3 | 2024 | 2227 | 0.140 |
Why?
|
| Male | 16 | 2024 | 60084 | 0.140 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 44 | 0.140 |
Why?
|
| Female | 17 | 2024 | 65500 | 0.140 |
Why?
|
| Aged | 10 | 2024 | 19080 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3084 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1641 | 0.130 |
Why?
|
| Risk Assessment | 5 | 2024 | 3316 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2016 | 13 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2020 | 548 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 233 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 2015 | 13 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2016 | 159 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2015 | 53 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2018 | 529 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 481 | 0.120 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2015 | 95 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 654 | 0.120 |
Why?
|
| Time Factors | 2 | 2014 | 6217 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2018 | 12129 | 0.110 |
Why?
|
| Incidence | 4 | 2024 | 3047 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 109 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 107 | 0.110 |
Why?
|
| Age Factors | 2 | 2024 | 2802 | 0.110 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 178 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 143 | 0.110 |
Why?
|
| Arterial Pressure | 1 | 2014 | 104 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 203 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2015 | 356 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2014 | 225 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 237 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2014 | 670 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 323 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1151 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 439 | 0.090 |
Why?
|
| Recurrence | 1 | 2014 | 1422 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2024 | 16021 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 560 | 0.080 |
Why?
|
| Texas | 3 | 2024 | 3555 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 2542 | 0.080 |
Why?
|
| Portal Pressure | 1 | 2008 | 5 | 0.080 |
Why?
|
| Decision Trees | 1 | 2008 | 49 | 0.080 |
Why?
|
| Hepatic Veins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Sclerotherapy | 1 | 2008 | 40 | 0.070 |
Why?
|
| Ligation | 1 | 2008 | 132 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 1259 | 0.070 |
Why?
|
| Decompression, Surgical | 1 | 2008 | 92 | 0.070 |
Why?
|
| Biomarkers | 3 | 2024 | 2946 | 0.070 |
Why?
|
| Esophagoscopy | 1 | 2008 | 156 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2008 | 121 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1430 | 0.070 |
Why?
|
| Serum Albumin, Human | 1 | 2024 | 10 | 0.060 |
Why?
|
| Platelet Count | 1 | 2024 | 133 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2024 | 107 | 0.060 |
Why?
|
| Prothrombin | 1 | 2024 | 24 | 0.060 |
Why?
|
| Acyltransferases | 1 | 2024 | 45 | 0.060 |
Why?
|
| Bilirubin | 1 | 2024 | 120 | 0.060 |
Why?
|
| Lipase | 1 | 2024 | 88 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3249 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2024 | 151 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2023 | 35 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2024 | 149 | 0.060 |
Why?
|
| Adolescent | 3 | 2020 | 19103 | 0.050 |
Why?
|
| North America | 1 | 2024 | 237 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2024 | 333 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2015 | 13887 | 0.050 |
Why?
|
| Prognosis | 2 | 2024 | 4507 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 1305 | 0.050 |
Why?
|
| Adult | 3 | 2018 | 29062 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 357 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 2838 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2020 | 123 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 209 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5047 | 0.040 |
Why?
|
| Keratin-18 | 1 | 2018 | 6 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 2025 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 214 | 0.040 |
Why?
|
| Serum | 1 | 2018 | 46 | 0.040 |
Why?
|
| Patient Participation | 1 | 2020 | 220 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 238 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 2830 | 0.040 |
Why?
|
| Child | 2 | 2015 | 24237 | 0.040 |
Why?
|
| Gastroenterology | 1 | 2020 | 191 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 451 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 313 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2024 | 1529 | 0.030 |
Why?
|
| Triglycerides | 1 | 2019 | 562 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 41 | 0.030 |
Why?
|
| Creatinine | 1 | 2018 | 380 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2019 | 330 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2586 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1590 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 383 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 541 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1472 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 280 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 1401 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1414 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3666 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1996 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4706 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6371 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 8863 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2015 | 3013 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8108 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 12348 | 0.010 |
Why?
|